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ABSTRACT
Objectives: In this article, we explore the future health
gain of different policy measures to reduce smoking prev-
alence: health education campaigns speciﬁcally aimed at
keeping (young) people from starting to smoke, cam-
paigns aimed at persuading smokers to quit, and tax
measures.
Methods: We drew up different policy scenarios based on
evaluations of several health promotion campaigns.
Implementing these into the dynamic multistate models,
we simulated smoking prevalence, loss of life-years, and
costs for several decades into the next century.
Results: In the short run, campaigns aimed at potential
“quitters” appear to be most effective in terms of health
gain. However, their effect fades away after several dec-
ades, while campaigns aimed at young “starters” or tax
measures in the end yield a larger and more lasting
decrease in smoking attributable disease burden.
Conclusion: Dynamic modeling is very useful tool in cal-
culating costs and effects of preventive public health
measures.
Keywords: cost of illness, dynamic modeling, public
health, scenario analysis, smoking.
Introduction
As in most developed countries, in the Netherlands
the burden of disease attributable to smoking is sub-
stantial. In 1997, cigarette smoking caused approx-
imately 23,000 deaths in the Netherlands, primarily
caused by lung cancer, coronary heart disease,
stroke, and chronic obstructive pulmonary disease
(COPD). In the Tobacco Paper: Tobacco Control
Policy, the Dutch government awards a high prior-
ity to the discouragement of tobacco smoking to
reduce the smoking-related burden of disease [1].
However, in spite of this tobacco paper, ﬁrm policy
measures have failed to appear, whereas smoking
prevalence among 10- to 14-year-old youths is grad-
ually increasing from 8% in 1990 to 14% in 1996
for boys and from 6% to 12% for girls [2]. An
increasing smoking prevalence among teenagers
implies an increasing burden of smoking-related
diseases in the future.
To describe the impact of increasing smoking
prevalence over time in terms of future burden and
costs of smoking-related diseases, a dynamic multi-
state model is needed [3–6]. These types of models
are able to integrate aging of the population, trends
in smoking prevalence, and trends in disease-
speciﬁc incidence for four smoking-related diseases.
More speciﬁcally, the model takes account of com-
peting death risks. We developed a dynamic multi-
state model, and as an example, we explored the
public health gain of different policy measures to
reduce smoking prevalence in terms of disability-
adjusted life-years (DALYs) and costs.
Methods
Model and Data
A dynamic multistate model describes the develop-
ment over time of demography, smoking preva-
lence, and smoking-related disease in the
Netherlands [7–10]. Four smoking-related diseases
are considered: lung cancer, coronary heart disease,
stroke, and COPD. In the model, the Dutch popu-
lation, which is divided into birth cohorts, is fol-
lowed from 1994. To understand the model,
imagine a person born in a given year. In each fol-
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lowing year, this person, if still alive, at certain age,
may start smoking and may have one or more dis-
eases. The changes in these characteristics are deter-
mined by transitions. As an example, with
probability, a 60-year-old smoker may become a 61-
year-old nonsmoker and may be diagnosed as a lung
cancer patient at the age of 65. The incidence of
smoking-related diseases depends on age, gender,
and smoking behavior. Data on incidence and mor-
tality of smoking-related diseases together with data
on changes in smoking behavior and demographics
of the Dutch population resulted in the future
number of smoking related patients for the years
1994 to 2050. Figure 1 presents the conceptual
structure of the model. The arrows in this ﬁgure
represent changes in health or smoking behavior.
Demographic data, incidence rates, 1994 preva-
lence rates, and disease-speciﬁc mortality rates were
the input data for the model. Demographic data on
migration, birth, and total mortality by gender and
age were obtained from Statistics Netherlands. To
obtain estimates for incidence and prevalence of
smoking-related diseases in 1994 in the Nether-
lands, data from several general practitioner regis-
trations were combined [11–13]. Mortality rates for
smoking-related diseases were estimated as the dif-
ference between mortality in the general population
and mortality among patients [14]. The 1994 gen-
der- and age-speciﬁc incidence and mortality rates
were used without time trends for the period 1994
to 2050. Remission from smoking-related diseases
was assumed to be zero.
Gender- and age-speciﬁc start and stop rates for
smoking were estimated from observed trends over
the period 1987 to 1994 using age-period-cohort
analysis. Smoking-speciﬁc incidence rates had to be
calculated from the observed gender- and age-spe-
ciﬁc incidence rates in the population and the rela-
tive risks or risk ratios of smokers and former
smokers for incidence of smoking-related diseases
[15]. The prevalence of smoking for 1994 and start
and stop rates are presented in Table 1, and the rel-
ative risks for four major smoking-related diseases
are presented in Table 2.
Figure 1 Basic structure of the multistate model.
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Table 1 Relative risks for smokers and former smokers,
men and women
Disease Age (years)
Smokers Former smokers
Men Women Men Women
Lung cancer 35–59 27.21 14.77 11.09 4.53
60–69 30.71 14.70 11.25 5.05
70–79 27.23 11.28 9.43 4.50
80+ 13.40 7.31 6.55 2.95
Coronary
heart
disease
35–59 3.36 3.61 1.99 1.61
60–69 2.06 2.43 1.44 1.14
70–79 1.49 1.63 1.19 1.18
80+ 1.23 1.00 1.04 1.00
Stroke 35–59 3.64 6.34 1.12 1.33
60–69 2.48 2.64 1.19 1.22
70–79 1.77 2.22 1.15 1.22
80+ 1.09 1.00 1.00 1.00
COPD 50–69 13.57 12.29 11.18 8.26
70+ 9.76 8.92 7.43 5.94
Table 2 Smoking-related input data, men and women
Age (years)
Men Women
Proportion* (1994) Rate Proportion* (1994) Rate
Never-smoker Smoker Start Quit Never-smoker Smoker Start Quit
10–14 0.97 0.03 0.072 0.97 0.03 0.023
15–19 0.76 0.22 0.057 0.041 0.77 0.21 0.047 0.046
20–24 0.59 0.34 0.045 0.041 0.60 0.32 0.031 0.034
25–29 0.49 0.40 0.03 0.034 0.49 0.37 0.02 0.029
30–34 0.42 0.43 0.018 0.028 0.41 0.39 0.012 0.027
35–39 0.37 0.44 0.016 0.40 0.39 0.007
40–44 0.33 0.44 0.019 0.43 0.37 0.009
45–49 0.31 0.43 0.022 0.46 0.34 0.01
50–54 0.30 0.42 0.025 0.50 0.31 0.012
55–59 0.30 0.40 0.029 0.55 0.28 0.013
60–64 0.30 0.38 0.033 0.60 0.24 0.015
*Proportion of former smokers equals 1 minus proportion never-smokers and proportion smokers.
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Scenarios
As an example, scenarios on antismoking measures
are considered. The Dutch Foundation on Smoking
and Health (StiVoRo) has evaluated its own ant-
ismoking campaigns over the period 1983 to 1991,
including three campaigns speciﬁcally aimed at
teenagers. The yearly reduction that was achieved
among young potential starters varied between 10
and 20%. In a recent meta-analysis of smoking pre-
vention studies a mean reduction of 30% was found
in the ﬁrst year [16]. Based on these studies, we have
assumed that a reduction of 20% in the numbers of
starters is possible.
A Dutch health education campaign encouraging
smokers to quit led to a 14% decrease in smoking
prevalence in the ﬁrst year. Similar effects among
smokers have been described in several other eval-
uation studies [17–20]. We have assumed a 14%
reduction in smoking prevalence in the ﬁrst years
and a 2% reduction in successive years.
The effect of tax measures is described in terms
of price elasticity: the percentage of change in smok-
ing prevalence per percentage of change in price.
Because Dutch data on price elasticity are lacking,
we have used data from the United Kingdom [21].
Based on these evaluations, the following alter-
native scenarios on future smoking prevalence are
formulated.
1. Reference scenario: Future smoking prevalence
is based on trend extrapolation.
2. Don’t start scenario: Continuous health pro-
motion aimed at keeping (young) people from
smoking; over a 3-year period (1998–2000) the
number of starters is reduced by 20%. For the
following years, it is assumed that this reduc-
tion can be maintained by periodically and sup-
plementary campaigns.
3. Quit scenario: Continuous health promotion
urges smokers to quit; in the ﬁrst year (1998) a
14% reduction of the smoking prevalence is
achieved. In successive years a reduction of 2%
of the smoking prevalence is maintained.
4. Tax scenario: Tax measures increase tobacco
prices with 50%. Price elasticity is -1.2 for
teenagers, -0.08 for adult men, and -0.23 for
adult women [21]. Consequently in the ﬁrst
year starting rates are 60% (1.2 times 50%
price reduction) lower than the reference value,
while quitting rates among male and female
smokers are 4% (0.08 times 50% price reduc-
tion) and 11.5% (0.23 times 50% price reduc-
tion) higher, respectively. Because of inﬂation,
prices among other effects on starting and quit-
ting rates diminish with 3% per year. Because
quitting rates have returned to their original
value in about 1 year, tax measures primarily
have an effect on the smoking behavior of teen-
agers [22].
Disability-Adjusted Life-Years Gained
Given the model estimates of prevalence and mor-
tality for the four smoking-related diseases for the
period 1998 to 2050, we calculated the total
number of life-years lost as the sum of the remain-
ing life expectancy at the age of death. Quality-of-
life losses for patients were calculated using Dutch
disease-speciﬁc quality-of-life weight [23,24]. Qual-
ity-of-life weights for four smoking-related diseases
are presented in Table 3. As an example, for an
average lung cancer patient 0.432 per year is lost as
a result of lung cancer, which means that 1 year
with lung cancer was considered to be equal to
0.568 years in perfect health.
The total amount of DALYs lost because of
smoking in a certain year was computed by adding
up years of life lost resulting from premature mor-
tality and the prevalence of smoking-related dis-
eases multiplied by the quality of life-weight. The
number of life-years saved in the different scenarios
is the difference of “reference” DALYs lost and
“alternative” DALYs lost.
Avoided Costs
For health-care costs, we used cost per person esti-
mates from the Cost of Illness in the Netherlands
study [25]. By multiplying disease-speciﬁc preva-
lence numbers and disease-speciﬁc costs per person
the total smoking-related costs can be calculated.
Costs to be avoided are difference of costs calcu-
lated in the reference scenario and the alternative
scenarios.
Sensitivity Analysis
In the different scenarios the effect of start and stop
smoking rates on DALYs gained and avoided costs
is calculated. The different scenarios can be inter-
preted as sensitivity analysis.
Table 3 Quality-of-life weights used in the model
Disease Quality-of-life weight
Lung cancer 0.432
Coronary heart disease 0.288
Stroke 0.609
COPD 0.314
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Results
In the reference scenario the prevalence of smoking
among men declines from 35% in 1995 to 29% in
2020 (Fig. 2). After that year the decline almost
stalls: in 2050 smoking prevalence is still 28%; for
women the smoking prevalence only slightly
decreased from 27% in 1995 to 24% in 2030 and
23% in 2050. In the don’t start scenario prevalence
is reduced to around 24% for males and 20% for
females in 2050, while the quitting scenario yields a
reduction to less than 16% for males and 14% for
females in 2050. In both scenarios the effect is
larger for men than for women. The tax scenario
reduces smoking prevalence among men to 24% in
2020, after which it slightly increase to 26%; for
women there is a reduction to 21% in 2025, after
which smoking prevalence remains constant. The
former smokers prevalence will rise in the quitting
scenario, whereas it decreases in the don’t start sce-
nario (Figs. 3 and 4).
In the don’t start scenario, it takes about 15 years
to see an effect on the number of DALYs lost each
year to smoking-related disease. From that moment
on, the health gain of programs aimed at teenagers
increases rapidly. The short-run health gain in the
quitting scenario is substantial but after reaching a
maximum of about 40,000 years in 2025 for males
and a maximum of about 50,000 in 2035 for
females, the annual number of life-years saved is
declining again. Cost to be avoided will be almost
€80 million for males and €100 million for females.
However, in the end the health gain and avoided
costs of the don’t start scenario will go beyond the
yield of the quitting scenario. The tax scenario
behaves very similar to the don’t start scenario but
runs faster, reaches a higher health gain and will
catch up with the quitting scenario earlier next
century.
In all scenarios a time lag between men and
women of about 5 years can be observed. The max-
Figure 2 Past and  and future smoking prevalence in different sce-
narios, men and  and women.
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Figure 3 Annual health gain in “alternative” scenarios compared to
the “reference” scenario, men and  and women.
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Table 4 Cost of smoking-related diseases in 1999 in million
euros, men and women
Disease Men Women Total
Lung cancer 74.7 29.7 104.4
Coronary heart disease 584.3 344.5 928.8
Stroke 416.9 611.8 1028.6
COPD 328.3 265.6 594.0
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imum (absolute) health gain is more or less the same
for both men and women.
Discussion
The results of this scenario study suggest that a
rather substantial number of health-adjusted life-
years are to be saved by programs aimed at reducing
smoking prevalence, especially among the young.
The application of DALYs to measure the returns
provides an indication of the health that is gained
more than merely the added years of life [3].
The largest reduction in smoking prevalence is
achieved in the quitting scenario. But there is no
way in which the WHO Health for All target of
20% smoking prevalence in the Netherlands can be
reached in 2000. In the quitting scenario, this goal
can be reached in 2015.
The pool of potential quitters is larger than the
pool of potential starters. Potential starters are pri-
marily youths from 10 to 30 years of age, whereas
most potential quitters are found in older age
groups. Therefore, in the short run the health gain
will be largest in the quitting scenario, as potential
quitters have a higher disease and mortality risk as
well. However, in the long run the health gain of the
quitting scenario diminishes, while at the same time
the returns of the don’t start and tax scenarios are
building up as a result of aging of the population.
The quitting scenario shows a time lag of about
10 years between males and females in reaching the
maximum health gain or the maximum costs to be
avoided. This observation can be explained by the
high percentage never smokers in older females.
Along with aging of the middle-aged women the
health gain and costs to be avoided will increase and
reach its maximum.
In the short run, campaigns aimed at adults
appear to be most effective in terms of health gain.
However, this health gain fades away, while cam-
paigns aimed at starters in the end yield a larger
effect.
Obviously the kind of disease modeling reported
here requires a fair degree of simpliﬁcation. For
instance, our Dutch model population is made up of
never-smokers, smokers, and former-smokers, i.e.,
groups we assume to be homogenous. Of course in
the real world many different types of smoking
behavior can be observed. We assume starters and
quitters to react alike to health education programs
and tax measures, whereas the degree of stubborn-
ness may differ substantially from one smoker to
the other. Therefore, especially the long-term
response to antismoking campaigns is hard to
appraise. Does the pool of smokers that can be
“converted” dry up in the course of time, leaving
only conﬁrmed smokers? What is the “shelf life” of
a tax measure? Will it still matter in a personal deci-
sion to quit or to stay away from smoking in the
next decades?
Considering these simpliﬁcations we think our
results should primarily be seen as fairly crude rep-
resentations of important trends and mechanisms in
the real world. Nevertheless, our simulations leave
but one conclusion: only rigorous and persistent
policies will substantially abate the health problem
associated with smoking.
Finally, we conclude that dynamic modeling can
be of great help in integrating data from different
sources to illustrate the cost and effects of preven-
tive public health policies.
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